FLOLIPID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLOLIPID (FLOLIPID).
Flolipid (simvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.
| Metabolism | Simvastatin is a prodrug; the lactone ring is hydrolyzed in vivo to the active β-hydroxyacid form. It is extensively metabolized by CYP3A4 and also undergoes glucuronidation. Major metabolites include the active β-hydroxyacid and 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives. |
| Excretion | Primarily hepatic metabolism with biliary excretion; approximately 90% of the dose is recovered in feces, and less than 10% in urine, mainly as metabolites. |
| Half-life | Terminal elimination half-life is approximately 3 to 4 hours; however, due to extensive enterohepatic recirculation, the clinical duration of action is longer, allowing for once-daily dosing. |
| Protein binding | More than 99% bound, primarily to albumin. |
| Volume of Distribution | Approximately 0.4 L/kg, indicating distribution into extravascular tissues; not extensively bound to tissues. |
| Bioavailability | Oral bioavailability is not applicable as Flolipid is an intravenous lipid emulsion; bioavailability is 100% via intravenous route. |
| Onset of Action | Oral: Onset of lipid-lowering effect occurs within 2 to 4 weeks of starting therapy; maximum effect typically seen after 4 to 8 weeks. |
| Duration of Action | Duration of lipid-lowering effect persists for at least 24 hours with once-daily dosing; continued effect requires sustained treatment; discontinuation leads to return to baseline lipid levels within several weeks. |
| Molecular Weight | 418.56 |
Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.
| Dosage form | SUSPENSION |
| Renal impairment | For GFR 30 to <60 mL/min/1.73 m²: maximum dose 2 mg once daily. For GFR <30 mL/min/1.73 m²: not recommended. |
| Liver impairment | Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. No specific Child-Pugh-based dosing adjustments provided; use with caution in mild hepatic impairment. |
| Pediatric use | For patients 8 years and older with heterozygous familial hypercholesterolemia: 2 mg orally once daily; may increase to 4 mg once daily after 4 weeks. |
| Geriatric use | No dose adjustment required; monitor for increased risk of myopathy and renal function in patients over 65 years. |
| 1st trimester | FLOLIPID (simvastatin) is contraindicated in pregnancy. Statins inhibit HMG-CoA reductase, which is essential for cholesterol synthesis required for fetal development. Use in first trimester may cause congenital anomalies. |
| 2nd trimester | Contraindicated. Potential for fetal harm; no established safe use. |
| 3rd trimester | Contraindicated. May cause decreased fetal growth and other adverse outcomes. |
Clinical note
Comprehensive clinical and safety monograph for FLOLIPID (FLOLIPID).
| Placental transfer | Simvastatin and its active metabolite are known to cross the placenta. Evidence from animal studies and limited human data suggest transfer with potential for fetal harm. |
| Breastfeeding | Simvastatin is present in breast milk; due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended. Alternative agents should be considered. |
■ FDA Black Box Warning
Simvastatin is contraindicated for use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone) and with gemfibrozil, cyclosporine, or danazol. Do not exceed 20 mg simvastatin daily with amiodarone, amlodipine, or ranolazine. Do not exceed 40 mg simvastatin daily with lomitapide or diltiazem. Avoid grapefruit juice. Increased risk of myopathy/rhabdomyolysis with these drugs.
| Serious Effects |
Active liver disease or unexplained persistent elevations of serum transaminasesHypersensitivity to simvastatin or any component of the formulationConcomitant use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products)PregnancyBreastfeeding
| Precautions | Myopathy/Rhabdomyolysis: Risk factors include age >65 years, female, renal impairment, uncontrolled hypothyroidism, and concomitant use of certain drugs (see Black Box Warning)., Hepatic effects: Persistent elevations in serum transaminases; recommend liver enzyme monitoring before and during treatment., Increased risk of diabetes mellitus: Small increase in fasting glucose and HbA1c., Interstitial lung disease: Rare cases reported., Use with caution in patients with predisposing factors for renal impairment. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) or 'Avoid'. |
| Teratogenic Risk | FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotoxicity. Second and third trimesters: Statins may reduce fetal cholesterol synthesis; risk of fetal harm cannot be excluded. Use only if pregnancy risk accepted. |
| Fetal Monitoring | Monitor maternal hepatic function (ALT, AST) and creatine kinase (CK) at baseline and periodically. Assess for muscle symptoms. In pregnancy, monitor fetal growth via ultrasound if inadvertent exposure. |
| Fertility Effects | No known significant effects on human fertility. Animal studies show no impairment of fertility at clinically relevant doses. |
| Food/Dietary | Grapefruit juice may modestly increase pitavastatin exposure; limit to small amounts (≤8 oz per day). No other significant food interactions; can be taken with or without food. Avoid excessive alcohol consumption due to potential hepatotoxicity. |
| Clinical Pearls | Flolipid (pitavastatin) is a potent statin with minimal CYP metabolism, reducing drug interactions; monitor for myopathy and hepatotoxicity; avoid in active liver disease; dose adjustment needed with renal impairment (CrCl <30 mL/min); no significant food effect, but grapefruit juice may modestly increase exposure; consider in patients with statin intolerance due to fewer CYP-mediated interactions. |
| Patient Advice | Take Flolipid at the same time each day, with or without food. · Avoid consuming large amounts of grapefruit juice; a small glass (8 oz) is acceptable. · Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise. · Notify your doctor if you develop jaundice, dark urine, or abdominal pain (signs of liver problems). · Continue a heart-healthy diet and exercise while taking this medication. · Do not double the dose if you miss one; take the next dose at the usual time. · Inform your doctor of all other medications, including over-the-counter drugs and supplements. |